ADDICT-CCU: Addiction in Intensive Cardiac Care Units
Study Details
Study Description
Brief Summary
Background:
Illicit drug use is a growing issue in Europe and leading cause of acute cardiac events in patients admitted to intensive cardiac care units. Indeed, cardiovascular complications are one of the main causes of death due to illicit drug use. However, its prevalence in patients hospitalized in intensive cardiac care units is unknown.
Objectives:
This large multicenter prospective study will assess the prevalence of illicit drug use in consecutive patients hospitalized in intensive cardiac care units by urine drug assay.
Eligibility:
-
Patient over 18 years old admitted to intensive Cardiac Care Unit (CCU) for any reason.
-
Without hospitalization for a planned interventional procedure.
-
Without hospitalization for more than 24 hours at any hospital facility before admission to the CCU.
Design:
-
Multicentre cohort study with a prospective enrolment of all consecutive patients admitted to the CCU to assess the prevalence of illicit drug use in 40 centers throughout France.
-
Participants will be screened with a physical exam, medical history and addiction survey.
-
Participants will be screened for drug use by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) and for tobacco by standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK).
-
Participants will be followed at 6 months of follow-up to assess the occurrence of cardiovascular events.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Objective:
Illicit drug use is a growing issue in Europe. In France, the prevalence of the illicit use of any drug is 11.4% of the population, ahead of Italy (10.6%), the United Kingdom (8.7%) and Germany (7.8%).
Cardiovascular complications are one of the main causes of death due to psychoactive drug use with more than 100,000 deaths per year are due to psychoactive drug use in France. Although the use of illicit drugs may be involved in several acute cardiac events in patients admitted to intensive cardiac care units (CCU), its prevalence in patients hospitalized in CCU is unknown. Interestingly, the current guidelines recommend only a declarative survey to investigate psychoactive drug use but no systematic urine or plasma screening. However, the rate of underreporting of these illegal substances remains high. To our knowledge, no study has ever consecutively assessed the prevalence of psychoactive drug use using systematic urine or plasma screening at the time of CCU admission. Because illicit drug use is a potential cardiovascular risk factor, accurate drug screening may initiate addictology management, modify the treatment and improve patient prognosis after a cardiovascular event.
The aim of the prospective ADDICT-CCU study is to assess the prevalence of illicit drug use in consecutive patients hospitalized in intensive cardiac care units by urine drug assay.
Study population:
All consecutive patients over 18 years admitted to the CCU during a 3 week recruitment period in 40 centers. The main exclusion criteria will be hospitalization for a planned interventional procedure, dementia, or hospitalization for more than 24 hours at any hospital facility before admission to the CCU. Informed consent will be obtained from all participants.
Design:
The investigators will conduct a multicentre cohort study with a prospective enrolment of all consecutive patients admitted to the CCU to assess the prevalence of psychoactive drug use in 40 centers throughout France. Anonymized data supporting the findings of this study will be collected using CleanwebTM software.
Outcome Measures:
The primary outcome will be the prevalence of at least one illicit drug among all consecutive patients hospitalized in the CCU.
The following psychoactive drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the CCU: i) cannabinoids (tetrahydrocannabinol [THC]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids.
In addition to the analysis of illicit drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychoactive drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine. Tobacco consumption will also be evaluated for each patient using a questionnaire with three choices: "never smoked," "smoking cessation" specifying the number of years, or "active smoking." Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of > 3 parts per million (ppm) signifying active smoking. Every patient will be provided with relevant instructions regarding the urine drug assay and exhaled CO measurement, and trained investigators will conduct the tests.
Regarding the secondary outcomes, participants will be followed at 6 months of follow-up to assess the occurrence of cardiovascular events.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| CCU patients All consecutive patients over 18 years admitted to the CCU. |
Other: urine test
The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol [THC]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
Other: Fagerström questionnaire
Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
Other: Exhaled carbon monoxide (CO) measurement
Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of > 3 parts per million (ppm) signifying active smoking.
|
Outcome Measures
Primary Outcome Measures
- Prevalence of psychoactive drug use assessed by urine drug assay at the time of patient admission. [Day 0]
The following psychoactive drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the CCU: i) cannabinoids (tetrahydrocannabinol [THC]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
Secondary Outcome Measures
- In-hospital major adverse events (MAE) [Up to 3 months]
In-hospital major adverse events (MAE) will be a combined outcome including: all-cause mortality, cardiogenic shock according to the European Society of Cardiology (ESC) guidelines, and requiring medical (catecholamines or inotropic agents) or mechanical haemodynamic support cardiac arrest: severe ventricular arrhytmia requiring defibrillation or anti-arrhytmic agents This outcome will be assessed by the clinical team in charge of the CCU during the hospitalization.
- Duration of the hospitalization [Up to 3 months]
The duration of the hospitalization of each patient in CCU and in the hospital.
- Combined major adverse clinical events (MACE). [6 months of follow-up]
MACE will be defined as all-cause death or unplanned hospitalization for acute cardiovascular reasons, confirmed by independent adjudication experts who will review medical documents according to the standardized definitions.
- All cause mortality [6 months of follow-up]
The adjudication of all-cause death was performed using the electronic French National Registry of Death (Institut National de la Statistique et des Etudes Economiques, INSEE registry).
- The occurrence of cardiovascular events [6 months of follow-up]
Other secondary outcomes will be assessed by independent adjudication experts will be as follows: all-cause death, cardiovascular mortality, nonfatal myocardial infarction, unstable angina, resuscitated cardiac arrest, hospitalizations for heart failure, heart transplantation or implantation of a mechanical circulatory support device, sustained ventricular arrhythmias, coronary revascularization, stroke, venous thromboembolic events, endocarditis and the implantation of a pacemaker or implantable cardioverter-defibrillator.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient over 18 years old admitted to Cardiac Intensive Care Unit (CCU) for any reason.
-
Oral informed consent.
Exclusion Criteria:
-
Hospitalization for a planned interventional procedure (percutaneous coronary intervention, coronary artery bypass graft surgery, transcatheter aortic valve implantation…).
-
Dementia.
-
Hospitalization for more than 24 hours at any hospital facility before admission to the CCU.
-
Patient under legal protection without the consent of the legal representative.
-
Patient with no social security.
-
Declining participation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Lariboisière, APHP, Cardiology | Paris | Ile De France | France | 75010 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
- Fondation Coeur et Recherche
Investigators
- Study Director: Jean-Guillaume DILLINGER, MD,PhD, Lariboisière Hospital, APHP, Paris
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP190870
- 2021-A00702-39